Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.34 |
| ▸ | CA2 | P00918 | 5/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12074270 | 1.00 | TDP1 (0.46) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18257731 | 1.00 | TDP1 (0.46) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18256781 | 0.91 | TDP1 (0.55) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18257730 | 0.91 | TDP1 (0.55) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL17029991 | 0.89 | TDP1 (0.62) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18257732 | 0.89 | TDP1 (0.62) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18256745 | 0.88 | TDP1 (0.65) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18257733 | 0.88 | TDP1 (0.65) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18256747 | 0.88 | TDP1 (0.65) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18257737 | 0.88 | TDP1 (0.65) | TDP1MAOAMAOBMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9211340-B2 | Means and methods of enhancing delivery to biological systems | CAPSUGEL BELGIUM (BE) | 2015-12-15 | — | — | US | disclosed |
| US-20100062050-A1 | MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS | CAPSUGEL BELGIUM (BE) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062050-A1 | MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS | SGTA, GHRHR, IL36G | TDP1 2906/4885MAOA 3911/4885MAOB 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.